Statin treatment and stroke recurrence: Impact of J-STARS
スポンサーリンク
概要
- 論文の詳細を見る
Beneficial effects of long-term HMG-CoA reductase inhibitor (statin) treatment for primary and secondary prevention of coronary heart disease (CHD) have been shown in several clinical trials and some of these statin trials in patients with established or high risk for CHD have shown that statins decrease stroke incidence. However, beneficial effects of statin for patients with chronic ischemic stroke and no histry of CHD remains to be clalified. The Japan Statin Treatment Against Recurrent Stroke (J-STARS) Study is a prospectivee randomised, open, blinded endpoint study designed to evaluate the effects of pravastatin 10mg/day in patients who preveously experienced an ischemic stroke other than cardioembolic infarction, but who do not have any CHD requiring statin treatment. We planed to enroll a total of 3, 000 patients, aged 45-80 years whc have serum cholesterol level of 180-240mg/dl. The primary endpoint is fatal and non-fatal stroke recurrence during the follow-up period of 5 year and the data collection phase of the study is expected to be completed by April 2010. Effects of statin on hs-CRP and carotid intima-media thickness will also be investigated as substudies of J-STARS. The detailed process for J-STARS protocol establishment have been presented in this symposium.
- 一般社団法人 日本脳卒中学会の論文
一般社団法人 日本脳卒中学会 | 論文
- Two cases with aphasia in the left putaminal damage and one case with visuospatial neglect in the right putaminal damage
- Alterations of plasma von Willebrand factor activity and the influence of anti-platelet drugs in acute cerebral infarction
- Carotid endarterectomy plaques correlation of clinical events and morphology.
- Stenting for stenosis of major cerebrovascular arteries.
- Cerebral infarction following antihypertensive therapy.